YOUR BUSINESS AUTHORITY
Springfield, MO
Bristol-Myers Squibb agreed to purchase MyoKardia for roughly $13 billion.
The deal would give Bristol-Meyers access to experimental heart disease therapy mavacamten.
The purchase agreement follows Bristol-Myers' $74 billion acquisition of Celgene last year.
Read more from CNBC.
Organizers hope to bolster client traffic to center city businesses.